Zobrazeno 1 - 10
of 424
pro vyhledávání: '"Toshihiro Nukiwa"'
Autor:
Yuji Minegishi, Ou Yamaguchi, Shunichi Sugawara, Shoichi Kuyama, Satoshi Watanabe, Kazuhiro Usui, Masahide Mori, Osamu Hataji, Toshihiro Nukiwa, Satoshi Morita, Kunihiko Kobayashi, Akihiko Gemma
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Lung cancer is most common among older individuals. However, polypharmacy and comorbidities, which are also more common in older individuals, can limit treatment options. Previous studies suggest that afatinib can be used safely a
Externí odkaz:
https://doaj.org/article/de52fc2a82794e4dbc60edd8b7b3a883
Autor:
Kimiyuki Ikeda, Hirofumi Chiba, Hirotaka Nishikiori, Arata Azuma, Yasuhiro Kondoh, Takashi Ogura, Yoshio Taguchi, Masahito Ebina, Hiroki Sakaguchi, Shogo Miyazawa, Moritaka Suga, Yukihiko Sugiyama, Toshihiro Nukiwa, Shoji Kudoh, Hiroki Takahashi, Pirfenidone Clinical Study Group in Japan
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-12 (2020)
Abstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder with a variable disease course. The recent advancement of antifibrotic therapy has increased the need for reliable and specific biomarkers. This study aimed to a
Externí odkaz:
https://doaj.org/article/b54bb130f11547e4a7e9aad2c5862ed8
Autor:
Takashi Ogura, Yoshikazu Inoue, Arata Azuma, Sakae Homma, Yasuhiro Kondoh, Katsumi Tanaka, Kaori Ochiai, Yukihiko Sugiyama, Toshihiro Nukiwa
Publikováno v:
Advances in Therapy. 40:1474-1493
Autor:
Tatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Prof Morihito Okada, Kozo Yoshimori, Ichiro Nakachi, Prof Akihiko Gemma, Koichi Azuma, Futoshi Kurimoto, Yukari Tsubata, Yuka Fujita, Hiromi Nagashima, Gyo Asai, Satoshi Watanabe, Masaki Miyazaki, Prof Koichi Hagiwara, Prof Toshihiro Nukiwa, Prof Satoshi Morita, Prof Kunihiko Kobayashi, Prof Makoto Maemondo
Publikováno v:
EBioMedicine, Vol 57, Iss , Pp 102861- (2020)
Summary: Background: The NEJ026 Phase 3 study demonstrated that erlotinib and bevacizumab (BE)-treated NSCLC patients with EGFR mutations had significantly better progression-free survival (PFS) than those treated with erlotinib alone (E). This study
Externí odkaz:
https://doaj.org/article/6f1997f9abf34fafabd3f2040e531e6b
Autor:
Eisaku, Miyauchi, Satoshi, Morita, Atsushi, Nakamura, Yukio, Hosomi, Kana, Watanabe, Satoshi, Ikeda, Masahiro, Seike, Yuka, Fujita, Koichi, Minato, Ryo, Ko, Toshiyuki, Harada, Koichi, Hagiwara, Kunihiko, Kobayashi, Toshihiro, Nukiwa, Akira, Inoue
Publikováno v:
Journal of Clinical Oncology. 40:3587-3592
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical Tri
Autor:
Taizou Hirano, Toshiaki Kikuchi, Naoki Tode, Arif Santoso, Mitsuhiro Yamada, Yoshiya Mitsuhashi, Riyo Komatsu, Takeshi Kawabe, Takeshi Tanimoto, Naoto Ishii, Yuetsu Tanaka, Hidekazu Nishimura, Toshihiro Nukiwa, Akira Watanabe, Masakazu Ichinose
Publikováno v:
EMBO Molecular Medicine, Vol 8, Iss 4, Pp 422-436 (2016)
Abstract Influenza virus epidemics potentially cause pneumonia, which is responsible for much of the mortality due to the excessive immune responses. The role of costimulatory OX40–OX40 ligand (OX40L) interactions has been explored in the non‐inf
Externí odkaz:
https://doaj.org/article/e942f85376eb4d95a3acbc6ab194b924
Autor:
Kunihiko Kobayashi, Hiromi Nagashima, Gyo Asai, Yosuke Kawashima, Shunichi Sugawara, Kana Watanabe, Naoki Furuya, Masahiro Seike, Ichiro Nakachi, Koichi Azuma, Satoshi Watanabe, Morihito Okada, Ou Yamaguchi, Yoshio Tsunezuka, Yukari Tsubata, Haruhiro Saito, Makoto Maemondo, Koichi Hagiwara, Masaki Miyazaki, Shunichiro Iwasawa, Kozo Yoshimori, Futoshi Kurimoto, Yuka Fujita, Toshihiro Nukiwa, Satoshi Morita, Tatsuro Fukuhara
Publikováno v:
The Lancet Respiratory Medicine. 10:72-82
Summary Background Bevacizumab is a promising candidate for combination treatment with epidermal growth factor receptor tyrosine-kinase inhibitors (eg, erlotinib), which could improve outcomes for patients with metastatic EGFR-mutant non-small-cell l
Autor:
Hiroki Takahashi, Moritaka Suga, Toshihiro Nukiwa, Shoji Kudoh, Masahito Ebina, Yasuhiro Kondoh, Shogo Miyazawa, Koji Sakamoto, Hiroki Sakaguchi, Takashi Ogura, Atsushi Suzuki, Yukihiko Sugiyama, Yoshio Taguchi, Arata Azuma
Publikováno v:
Chest. 160:1372-1376
Autor:
Toshihiro, Nukiwa
Publikováno v:
Brain and nerve = Shinkei kenkyu no shinpo. 74(9)
The neurophysiological background of oriental bodywork based on breathing methods is poorly understood. Recently, experimental techniques using genetically engineered animals have been applied to identify and analyze the functions of motor columns su
Autor:
Ryo Okuda, Takashi Ogura, Shu Hisata, Tomohisa Baba, Yasuhiro Kondoh, Takafumi Suda, Takeshi Johkoh, Tae Iwasawa, Hiromi Tomioka, Masashi Bando, Arata Azuma, Yoshikazu Inoue, Toru Arai, Yutaro Nakamura, Atsushi Miyamoto, Yasunari Miyazaki, Hirofumi Chiba, Haruyuki Ishii, Naoki Hamada, Yasuhiro Terasaki, Ichiro Kuwahira, Shinji Sato, Shingo Kato, Takuji Suzuki, Susumu Sakamoto, Yasuhiko Nishioka, Noboru Hattori, Naozumi Hashimoto, Satoshi Morita, Nao Ichihara, Hiroaki Miyata, Koichi Hagiwara, Toshihiro Nukiwa, Kunihiko Kobayashi
Publikováno v:
Respiratory investigation.
Numerous studies investigated patients with IPF; however, only a few examined patients with idiopathic interstitial pneumonias (IIPs).The Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry, which was initiated in December 2016, is a multicen